Study of Minimal Residual Disease in Pancreatic Ductal Adenocarcinoma Using Liquid Biopsies After Surgery and Chemotherapy

What this Trial Is About

Researchers are investigating pancreatic ductal adenocarcinoma PDAC, the most common type of pancreatic cancer, focusing on the use of circulating tumor DNA ctDNA as a marker to detect residual disease and predict the risk of cancer recurrence. This study aims to confirm that ctDNA detected after treatment, including surgery and chemotherapy, can identify patients with a high risk of recurrence and improve clinical practice. It is part of the larger European GUIDE.MRD project, developing international standards for ctDNA diagnostics. The study involves patients in France who undergo potentially curative surgery for PDAC. Blood samples will be collected repeatedly at specific times to analyze ctDNA levels. The study will also compare different commercial ctDNA tests to determine the most effective at various time points. The researchers will assess ctDNA levels before and after chemotherapy and explore the relationship between ctDNA detection and imaging results. Participants will be followed for up to three years after treatment, during which their blood samples, disease-free survival, time to clinical and molecular recurrence, and overall survival will be monitored. The study will also evaluate how ctDNA analysis correlates with CT scan findings and whether it can guide the timing of imaging. Patients consent and compliance will be closely managed, and their health information will be securely stored for research.

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)